MX2021013609A - Materiales y métodos para tratar la degeneración macular relacionada con la edad. - Google Patents

Materiales y métodos para tratar la degeneración macular relacionada con la edad.

Info

Publication number
MX2021013609A
MX2021013609A MX2021013609A MX2021013609A MX2021013609A MX 2021013609 A MX2021013609 A MX 2021013609A MX 2021013609 A MX2021013609 A MX 2021013609A MX 2021013609 A MX2021013609 A MX 2021013609A MX 2021013609 A MX2021013609 A MX 2021013609A
Authority
MX
Mexico
Prior art keywords
materials
methods
macular degeneration
related macular
treating age
Prior art date
Application number
MX2021013609A
Other languages
English (en)
Inventor
Howard J Federoff
Sudhakar Raja Subramaniam
Sonali Nashine
M Cristina Kenney
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2021013609A publication Critical patent/MX2021013609A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

En la presente se describen materiales y métodos para el tratamiento de la degeneración macular relacionada con la edad mediante la administración de una combinación de fenofibrato y un inhibidor de esterasa (p. ej., kaempferol o telmisartán).
MX2021013609A 2019-05-06 2020-05-06 Materiales y métodos para tratar la degeneración macular relacionada con la edad. MX2021013609A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962843624P 2019-05-06 2019-05-06
PCT/US2020/031610 WO2020227366A1 (en) 2019-05-06 2020-05-06 Materials and methods for treating age-related macular degeneration

Publications (1)

Publication Number Publication Date
MX2021013609A true MX2021013609A (es) 2022-04-06

Family

ID=73051679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013609A MX2021013609A (es) 2019-05-06 2020-05-06 Materiales y métodos para tratar la degeneración macular relacionada con la edad.

Country Status (7)

Country Link
US (1) US20220211654A1 (es)
EP (1) EP3965747A4 (es)
JP (1) JP2022531484A (es)
BR (1) BR112021022270A2 (es)
CA (1) CA3137034A1 (es)
MX (1) MX2021013609A (es)
WO (1) WO2020227366A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842722B2 (en) * 2003-12-19 2010-11-30 Alcon, Inc. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
PL1768657T3 (pl) * 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
RU2489146C1 (ru) * 2012-07-11 2013-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения "сухой" формы возрастной макулярной дегенерации
JP2016539098A (ja) * 2013-10-25 2016-12-15 チルドレンズ メディカル センター コーポレーション 網膜の血管障害を治療又は予防する方法
US20190049465A1 (en) * 2016-02-06 2019-02-14 Georgetown University Compositions and methods for the diagnosis and treatment of age-related macular degeneration
CN106880626A (zh) * 2017-03-14 2017-06-23 何伟 山奈酚在制备预防和治疗视网膜损伤性疾病药物中的应用
MX2021009413A (es) * 2019-02-05 2022-01-18 Univ California Materiales y métodos para tratar una enfermedad neurodegenerativa.

Also Published As

Publication number Publication date
JP2022531484A (ja) 2022-07-06
CA3137034A1 (en) 2020-11-12
BR112021022270A2 (pt) 2022-01-11
EP3965747A4 (en) 2023-06-07
WO2020227366A1 (en) 2020-11-12
US20220211654A1 (en) 2022-07-07
EP3965747A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
AU2021200309B2 (en) Compositions and methods for treatment of diabetic macular edema
JOP20210060A1 (ar) معدلات لمضاد تريبسين ألفا-1
SG10201901010PA (en) Combination therapy for treating a paramyxovirus
MX2022001004A (es) Inhibidores de enzimas.
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
WO2018039475A8 (en) Use of pridopidine for treating dystonias
EA201890728A2 (ru) Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
EA202092540A1 (ru) Комбинации для лечения рака
WO2020055858A8 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
MX2022000811A (es) Inhibidores de enzimas.
WO2020047144A3 (en) Ophthalmic formulations, process for preparing the same and method for administering the same
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2021009413A (es) Materiales y métodos para tratar una enfermedad neurodegenerativa.
MX2021013609A (es) Materiales y métodos para tratar la degeneración macular relacionada con la edad.
MX2021008865A (es) Inhibidores de magl para usarse para tratar enfermedades antecedentes.
MX2021004215A (es) Combinaciones de inhibidores de la replicación del virus de la gripe.
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.